Q1 Earnings Forecast for Arvinas Issued By Leerink Partnrs

Arvinas, Inc. (NASDAQ:ARVN) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Arvinas in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will earn ($0.50) per share for the quarter. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share. Leerink Partnrs also issued estimates for Arvinas’ Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.79) EPS, FY2025 earnings at ($2.89) EPS and FY2026 earnings at ($3.53) EPS.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. During the same period last year, the business posted ($2.53) EPS.

Several other analysts have also recently commented on the stock. Guggenheim reaffirmed a “buy” rating on shares of Arvinas in a research note on Thursday, December 12th. Barclays dropped their target price on Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. BMO Capital Markets decreased their price target on Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 20th. Stephens began coverage on shares of Arvinas in a research note on Monday, November 18th. They set an “overweight” rating and a $55.00 price objective for the company. Finally, Wedbush reissued an “outperform” rating and issued a $57.00 target price on shares of Arvinas in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $61.45.

Arvinas Price Performance

Arvinas stock opened at $17.68 on Monday. The firm’s 50-day moving average is $19.33 and its two-hundred day moving average is $23.36. The stock has a market capitalization of $1.21 billion, a P/E ratio of -3.79 and a beta of 1.88. Arvinas has a 12-month low of $16.61 and a 12-month high of $53.08.

Hedge Funds Weigh In On Arvinas

A number of institutional investors and hedge funds have recently bought and sold shares of ARVN. Handelsbanken Fonder AB boosted its stake in shares of Arvinas by 17.4% in the third quarter. Handelsbanken Fonder AB now owns 19,525 shares of the company’s stock valued at $481,000 after purchasing an additional 2,900 shares during the period. Exchange Traded Concepts LLC grew its stake in shares of Arvinas by 37.0% during the third quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock valued at $164,000 after acquiring an additional 1,798 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of Arvinas in the third quarter worth about $39,000. Assenagon Asset Management S.A. purchased a new position in Arvinas in the third quarter valued at about $3,442,000. Finally, E. Ohman J or Asset Management AB increased its holdings in Arvinas by 20.1% during the 3rd quarter. E. Ohman J or Asset Management AB now owns 29,830 shares of the company’s stock worth $735,000 after purchasing an additional 5,000 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.